Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Albane Courjaud"'
Autor:
Monsif Bouaboula, Laurent Debussche, Carlos Garcia-Echeverria, Hong Cheng, Bruno Filoche-Rommé, Gary McCort, Fabienne Thompson, Victor Certal, Michel Tabart, Frank Halley, Youssef El-Ahmad, Laurent Schio, Pierre-Yves Abecassis, Dinesh S. Bangari, Anne Caron, Laurent Besret, Joon Sang Lee, Jack Pollard, Hui Cao, Rosalia Arrebola, Albane Courjaud, Dietmar Hoffmann, Mikhail N. Levit, Jessica McManus, Andrew T. Hebert, Zhuyan Guo, Malvika Koundinya, Fangxian Sun, Jane Cheng, Maysoun Shomali
1022 gene signature from RNAseq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c10eddd92e318753beaf14063960214f
https://doi.org/10.1158/1535-7163.22520766
https://doi.org/10.1158/1535-7163.22520766
Autor:
Monsif Bouaboula, Laurent Debussche, Carlos Garcia-Echeverria, Hong Cheng, Bruno Filoche-Rommé, Gary McCort, Fabienne Thompson, Victor Certal, Michel Tabart, Frank Halley, Youssef El-Ahmad, Laurent Schio, Pierre-Yves Abecassis, Dinesh S. Bangari, Anne Caron, Laurent Besret, Joon Sang Lee, Jack Pollard, Hui Cao, Rosalia Arrebola, Albane Courjaud, Dietmar Hoffmann, Mikhail N. Levit, Jessica McManus, Andrew T. Hebert, Zhuyan Guo, Malvika Koundinya, Fangxian Sun, Jane Cheng, Maysoun Shomali
Primary treatment for estrogen receptor-positive (ER+) breast cancer is endocrine therapy. However, substantial evidence indicates a continued role for ER signaling in tumor progression. Selective estrogen receptor degraders (SERD), such as fulvestra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b86af78b2f4b0ea0bc017ba86b84056
https://doi.org/10.1158/1535-7163.c.6542763
https://doi.org/10.1158/1535-7163.c.6542763
Autor:
Monsif Bouaboula, Laurent Debussche, Carlos Garcia-Echeverria, Hong Cheng, Bruno Filoche-Rommé, Gary McCort, Fabienne Thompson, Victor Certal, Michel Tabart, Frank Halley, Youssef El-Ahmad, Laurent Schio, Pierre-Yves Abecassis, Dinesh S. Bangari, Anne Caron, Laurent Besret, Joon Sang Lee, Jack Pollard, Hui Cao, Rosalia Arrebola, Albane Courjaud, Dietmar Hoffmann, Mikhail N. Levit, Jessica McManus, Andrew T. Hebert, Zhuyan Guo, Malvika Koundinya, Fangxian Sun, Jane Cheng, Maysoun Shomali
supplemental methods, data and figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3813137435b6e50ede54df16b76c6dfc
https://doi.org/10.1158/1535-7163.22520769.v1
https://doi.org/10.1158/1535-7163.22520769.v1
Autor:
Chrystelle Girardet, Magali Mathieu, François Vallée, Jacques Le-Roux, Fangxian Sun, Laurence Fabien, Corinne Terrier, Celine Ginesty, Bruno Filoche-Romme, Florence Gruss-Leleu, Maysoun Shomali, Monsif Bouaboula, Sylvie Beccari, Pascal Desmazeau, Gilles Lebourg, Tsiala Benard, Victor Certal, Pascale Vicat, Andrew Hebert, Carlos Garcia-Echeverria, Laurent Schio, Youssef El-Ahmad, Gary Mccort, Claire Muller, Maurice Brollo, Mikhail Levit, Luc Bertin, Hong Cheng, Véronique Loyau, Valerie Steier, Fabienne Thompson, Audrey Louboutin, Fabienne Pilorge, Alexey Rak, Frank Halley, Patrick Richepin, Christelle Perrault, Pierre-Yves Abecassis, Michel Tabart, Albane Courjaud
Publikováno v:
Journal of Medicinal Chemistry. 63:512-528
More than 75% of breast cancers are estrogen receptor alpha (ERα) positive (ER+), and resistance to current hormone therapies occurs in one-third of ER+ patients. Tumor resistance is still ERα-dependent, but mutations usually confer constitutive ac
Autor:
Youssef El-Ahmad, Hong Cheng, Fabienne Thompson, Monsif Bouaboula, Jack Pollard, Gary Mccort, Andrew Hebert, Carlos Garcia-Echeverria, Michel Tabart, Fangxian Sun, Laurent Schio, Joon Sang Lee, Dinesh S. Bangari, Jane Cheng, Laurent Besret, Hui Cao, Dietmar Hoffmann, Maysoun Shomali, Rosalia Arrebola, Zhuyan Guo, Anne Caron, Laurent Debussche, Frank Halley, Bruno Filoche-Romme, Albane Courjaud, Mikhail Levit, Malvika Koundinya, Jessica McManus, Victor Certal, Pierre-Yves Abecassis
Publikováno v:
Molecular cancer therapeutics. 20(2)
Primary treatment for estrogen receptor-positive (ER+) breast cancer is endocrine therapy. However, substantial evidence indicates a continued role for ER signaling in tumor progression. Selective estrogen receptor degraders (SERD), such as fulvestra
Autor:
Maysoun Shomali, Youssef El-Ahmad, Frank Halley, Jane Cheng, Michael Weinstein, Muchun Wang, Fangxian Sun, Natalia Malkova, Mikhail Levit, Malvika Koundinya, Zhuyan Gou, Andrew Hebert, Jessica McManus, Dietmar Hoffman, Hui Cao, Joonil Jung, Jack Pollard, Sylvie Vincent, Timothy Ackerson, Francisco Adrian, Chris Winter, Victoria Richon, Hong Chen, Karl Hsu, Joanne Lager, Albane Courjaud, Rosalia Arrebola, Laurent Besret, Pierre-Yves Abecassis, Laurent Schio, Gary McCort, Michel Tabart, Victor Certal, Fabienne Thompson, Bruno Filoche-Rommé, Laurent Debussche, Patrick Cohen, Carlos Garcia-Echeverria, Monsif Bouaboula
Publikováno v:
Cancer Research. 78:5775-5775
Nearly 70% or more of newly diagnosed cases of breast cancer (BC) are estrogen receptor positive (ER+) where endocrine therapy is a primary treatment. However, substantial evidence describes a continued role of ER signaling in tumor progression, wher
Autor:
Judith Sudhalter, Qiang Gao, Stephan Reiling, Isabelle Schreiber, Albane Courjaud, Jack Pollard, Eric Yang, Luc Bonnet, Joshua Murtie, Carlos Garcia-Echeverria, Matthieu Barrague, Fangxian Sun, Timothy He, Claudine Grepin, Monsif Bouaboula, Francisco Adrian, Bailin Zhang, Malvika Koundinya, M. Paola Castaldi, Gaetan Touyer, Bruno Lionne, Mark Munson, Richard Newcombe, Isabelle Menguy, Rosalia Arrebola, Stuart Licht, Yanjun Wang, Christopher Winter, Ronald Tomlinson, Patricia Gee, Hui Cao, Christelle Perrault, Stephanie Vougier, Aaron J. Morris, David Harper, Brigitte Benhamou, Hong Cheng, Ivan Cornella-Taracido, Daniel Simard
Publikováno v:
Cell Chemical Biology. 25:705-717.e11
Summary Activating KRAS mutations are major oncogenic drivers in multiple tumor types. Synthetic lethal screens have previously been used to identify targets critical for the survival of KRAS mutant cells, but their application to drug discovery has
Autor:
Brigitte Benhamou, Ivan Cornella-Taracido, Christelle Perrault, Stephanie Vougier, Bruno Lionne, Ronald Tomlinson, Francisco Adrian, Hui Cao, David P. Harper, Maria Paola Castaldi, Isabelle Schreiber, Jack Pollard, Malvika Koundinya, Monsif Bouaboula, Albane Courjaud, Gaetan Touyer, Rosalia Arrebola, Luc Bonnet, Aaron J. Morris, Daniel Simard, Stephan Reiling, Judith Sudhalter, Carlos Garcia-Echeverria, Claudine Grepin, Isabelle Menguy
Publikováno v:
Cancer Research. 73:2243-2243
Activating KRAS mutations are oncogenic and prevalent in multiple tumor types, being found in as high as 90% of pancreatic carcinomas and 50% of colorectal carcinomas. In spite of its attractiveness for therapeutic intervention to date no KRAS-target